Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the man...
Gespeichert in:
Veröffentlicht in: | Oncogene 2005-12, Vol.24 (54), p.8061-8075 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the
MDR1
gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the
MDR1
locus, concomitant with
MDR1
upregulation mediated by transcriptional activation and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the
MDR1
promoter.
MDR1
upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modifications occurred within the 5′ hypomethylated region of
MDR1
, directly correlating with
MDR1
upregulation. Specifically, drug-induced upregulation of
MDR1
was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the
MDR1
locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the
MDR1
promoter and enhance the MDR phenotype. |
---|---|
ISSN: | 0950-9232 1476-5594 |
DOI: | 10.1038/sj.onc.1208955 |